Last reviewed · How we verify
HEC113995 PA•H2O tablets
At a glance
| Generic name | HEC113995 PA•H2O tablets |
|---|---|
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HEC113995 PA•H2O tablets CI brief — competitive landscape report
- HEC113995 PA•H2O tablets updates RSS · CI watch RSS
- Sunshine Lake Pharma Co., Ltd. portfolio CI